Wet Age-Related Macular Degeneration

Ocular Therapeutix obtained FDA support to use the phase 3 SOL-R trial as the next step in the regulatory process for Axpaxli, according to a press release.

Nearly 2 years after it voluntarily recalled Susvimo, Genentech recently announced plans to reintroduce the implant.

In this Healio Video Perspective from the ASRS meeting, Ashkan M. Abbey, MD, of Texas Retina Associates discusses data from the DAVIO 2 trial investigating EYP-1901 for the treatment of wet age-related macular degeneration.

In this Healio Video Perspective from the ASRS meeting, Pravin U. Dugel, MD, of Ocular Therapeutix discusses the phase 3 program for Axpaxli, an axitinib implant for wet age-related macular degeneration.

One intravitreal injection of 4D-150 helped reduce the mean annualized anti-VEGF injection rate in patients with wet age-related macular degeneration, according to a study presented at the American Society of Retina Specialists meeting.

Genentech is set to reintroduce Susvimo for patients with wet age-related macular degeneration nearly 2 years after it voluntarily recalled the ocular implant, according to a press release.

The FDA approved the Vabysmo 6-mg single-dose prefilled syringe for the treatment of wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion, according to a Genentech press release.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David Kirn, MD, of 4D Molecular Therapeutics provides an update on two candidates for retinal diseases.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Victor Perlroth, MD, CEO of Kodiak Sciences, provides an overview of the company’s ongoing retinal therapy programs.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Russ Trenary, president and CEO of Outlook Therapeutics, discusses the development of ONS-5010.